Concurrent Investment Advisors LLC Boosts Position in Zoetis Inc. $ZTS

Concurrent Investment Advisors LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 98.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,405 shares of the company’s stock after buying an additional 17,105 shares during the period. Concurrent Investment Advisors LLC’s holdings in Zoetis were worth $2,472,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank purchased a new stake in Zoetis during the 4th quarter worth $734,425,000. Flossbach Von Storch SE purchased a new stake in Zoetis during the 2nd quarter worth $302,601,000. BlackRock Inc. increased its holdings in Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. purchased a new position in Zoetis in the first quarter valued at about $286,660,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZTS. HSBC decreased their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. BNP Paribas Exane dropped their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Barclays reduced their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Zacks Research downgraded shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Finally, Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $101.08.

Zoetis Stock Down 3.0%

Shares of Zoetis stock opened at $73.56 on Wednesday. The business has a 50-day moving average of $75.61 and a 200-day moving average of $92.87. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market capitalization of $30.40 billion, a PE ratio of 12.12, a P/E/G ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $152.12.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.